George Migausky V
Known title: DirectorCIK: 0001134365
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.
Transaction History
| RGNX | ▲ Buy | Grant | 9,807 | $0 | 5/29/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 7,768 | $0 | 5/30/2025 | View on chart |
| IMVT | ▲ Buy | Grant | 16,188 | $0 | 4/1/2025 | View on chart |
| RGNX | ▲ Buy | Grant | 4,790 | $0 | 5/31/2024 | View on chart |
| IMVT | ▲ Buy | Grant | 11,255 | $0 | 4/2/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 4,200 | $163K | 12/1/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 3,478 | $138K | 12/1/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 5,022 | $203K | 12/1/2023 | View on chart |
| RGNX | ▲ Buy | Grant | 3,486 | $0 | 6/2/2023 | View on chart |
| IMVT | ▲ Buy | Grant | 12,523 | $0 | 4/12/2023 | View on chart |
| IMVT | ▲ Buy | Grant | 21,059 | $0 | 8/17/2022 | View on chart |
| RGNX | ▲ Buy | Grant | 3,010 | $0 | 6/3/2022 | View on chart |
| IMVT | ▲ Buy | Grant | 21,726 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.